FDA Approves Lamzede (velmanase alfa-tycv) for the Treatment of Alpha-Mannosidosis

First and only enzyme replacement therapy for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients Ultra-rare progressive disease presents with wide range of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news